IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment
Open Access
- 1 February 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (3) , 980-987
- https://doi.org/10.1182/blood-2003-03-0981
Abstract
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease arising from the clonal expansion of a stem cell expressing the bcr/abl oncogene. CML patients frequently respond to treatment with interferon-α (IFN-α), even though the mechanisms of the response remain unclear. In the present study, we evaluated the role of IFN-α in differentiation and activity of monocyte-derived dendritic cells (DCs) from CML patients as well as in modulation of the cell response to lipopolysaccharide (LPS). Treatment of CML monocytes with IFN-α and granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in the rapid generation of activated DCs (CML-IFN-DCs) expressing interleukin-15 (IL-15) and the antiapoptotic bcl-2 gene. These cells were fully competent to induce IFN-γ production by cocultured autologous T lymphocytes and expansion of CD8+ T cells. LPS treatment of CML-IFN-DCs, but not of immature DCs generated in the presence of IL-4/GM-CSF, induced the generation of CD8+ T cells reactive against autologous leukemic CD34+ cells. Altogether, these results suggest that (1) the generation of highly active monocyte-derived DCs could be important for the induction of an antitumor response in IFN-treated CML patients and (2) IFN-α can represent a valuable cytokine for the rapid generation of active monocyte-derived DCs to be utilized for vaccination strategies of CML patients. (Blood. 2004;103:980-987)Keywords
This publication has 49 references indexed in Scilit:
- Novel targeted and immunotherapeutic strategies in chronic myeloid leukemiaSeminars in Hematology, 2003
- Imatinib alone and in combination for chronic myeloid leukemiaSeminars in Hematology, 2003
- Sti-571 in Chronic Myelogenous LeukaemiaBritish Journal of Haematology, 2002
- Imatinib: the first 3 yearsEuropean Journal Of Cancer, 2002
- IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cellsInternational Immunology, 2002
- Current Therapy of Chronic Myelogenous Leukemia.Internal Medicine, 2002
- Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- CML vaccines as a paradigm of the specific immunotherapy of cancerBlood Reviews, 2000
- The neglected role of type I interferon in the T-cell response: implications for its clinical useImmunology Today, 1996
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994